Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche, Aspreva Evaluating Filing Options For CellCept In Lupus Following Phase III Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

Preliminary data from the induction phase of the trial show the study did not meet its primary superiority endpoint.

You may also be interested in...



Aspreva, Roche Will Not Advance CellCept For Lupus Nephritis

Aspreva continues Phase III trial of CellCept to treat autoimmune disease pemphigus vulgaris.

Aspreva, Roche Will Not Advance CellCept For Lupus Nephritis

Aspreva continues Phase III trial of CellCept to treat autoimmune disease pemphigus vulgaris.

Aspreva Will Not Pursue CellCept For Myasthenia Gravis After Phase III Failure

Study of Roche drug fails to meet both primary and secondary endpoints, company says.

Topics

UsernamePublicRestriction

Register

OM016276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel